Theratyping of the Rare CFTR Genotype A559T in Rectal Organoids and Nasal Cells Reveals a Relevant Response to Elexacaftor (VX-445) and Tezacaftor (VX-661) Combination

Despite the promising results of new CFTR targeting drugs designed for the recovery of F508del- and class III variants activity, none of them have been approved for individuals with selected rare mutations, because uncharacterized CFTR variants lack information associated with the ability of these c...

Descripción completa

Detalles Bibliográficos
Autores principales: Kleinfelder, Karina, Villella, Valeria Rachela, Hristodor, Anca Manuela, Laudanna, Carlo, Castaldo, Giuseppe, Amato, Felice, Melotti, Paola, Sorio, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299407/
https://www.ncbi.nlm.nih.gov/pubmed/37373505
http://dx.doi.org/10.3390/ijms241210358

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299407/
https://www.ncbi.nlm.nih.gov/pubmed/37373505
http://dx.doi.org/10.3390/ijms241210358

Ejemplares similares